 Douglas Merkel
Concepts (89)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 9 | 2020 | 2699 | 0.430 |
Why?
| | Quality of Life | 3 | 2020 | 1342 | 0.240 |
Why?
| | Fatigue | 1 | 2002 | 166 | 0.220 |
Why?
| | Anemia | 1 | 2002 | 124 | 0.220 |
Why?
| | Health Care Surveys | 1 | 2002 | 275 | 0.220 |
Why?
| | Mortality | 1 | 2002 | 144 | 0.210 |
Why?
| | Flow Cytometry | 2 | 1992 | 682 | 0.180 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2020 | 234 | 0.180 |
Why?
| | Severity of Illness Index | 1 | 2002 | 1686 | 0.160 |
Why?
| | Neoplasms | 2 | 2015 | 2618 | 0.140 |
Why?
| | Patient Care Planning | 1 | 2015 | 80 | 0.140 |
Why?
| | Neoplasms, Hormone-Dependent | 2 | 2012 | 38 | 0.140 |
Why?
| | Self Care | 1 | 2015 | 151 | 0.130 |
Why?
| | Health Promotion | 1 | 2015 | 153 | 0.130 |
Why?
| | Patient-Centered Care | 1 | 2015 | 188 | 0.120 |
Why?
| | Radioisotope Teletherapy | 1 | 1992 | 4 | 0.120 |
Why?
| | Mastectomy, Modified Radical | 1 | 1992 | 6 | 0.120 |
Why?
| | Cobalt Radioisotopes | 1 | 1992 | 19 | 0.120 |
Why?
| | Aromatase Inhibitors | 1 | 2012 | 27 | 0.110 |
Why?
| | Spectrophotometry | 1 | 1992 | 106 | 0.110 |
Why?
| | Patient Education as Topic | 1 | 2015 | 340 | 0.110 |
Why?
| | Arthralgia | 1 | 2012 | 34 | 0.110 |
Why?
| | Antineoplastic Agents | 1 | 2002 | 2268 | 0.110 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 1990 | 106 | 0.100 |
Why?
| | Health Status | 1 | 2011 | 342 | 0.090 |
Why?
| | Carcinoma | 1 | 1992 | 412 | 0.090 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2004 | 2277 | 0.090 |
Why?
| | Dietary Fats | 1 | 2006 | 142 | 0.080 |
Why?
| | Female | 11 | 2020 | 42244 | 0.070 |
Why?
| | Middle Aged | 8 | 2020 | 23948 | 0.070 |
Why?
| | Aged, 80 and over | 3 | 2020 | 6195 | 0.070 |
Why?
| | Receptor, erbB-3 | 1 | 2004 | 17 | 0.070 |
Why?
| | DNA | 1 | 1990 | 1246 | 0.070 |
Why?
| | Aged | 6 | 2020 | 17394 | 0.060 |
Why?
| | Receptor, erbB-2 | 1 | 2004 | 182 | 0.060 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2015 | 1156 | 0.060 |
Why?
| | Prognosis | 3 | 2020 | 3522 | 0.060 |
Why?
| | Adult | 6 | 2020 | 24525 | 0.050 |
Why?
| | Humans | 11 | 2020 | 79512 | 0.050 |
Why?
| | Ferredoxin-NADP Reductase | 1 | 2020 | 15 | 0.050 |
Why?
| | Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2020 | 25 | 0.050 |
Why?
| | Ploidies | 2 | 1990 | 37 | 0.050 |
Why?
| | Follow-Up Studies | 2 | 2020 | 3553 | 0.040 |
Why?
| | Germ-Line Mutation | 1 | 2020 | 294 | 0.040 |
Why?
| | Combined Modality Therapy | 2 | 1992 | 1602 | 0.040 |
Why?
| | Antibodies, Monoclonal | 1 | 2004 | 1367 | 0.040 |
Why?
| | Lymphatic Metastasis | 2 | 2006 | 465 | 0.040 |
Why?
| | Genotype | 1 | 2020 | 1776 | 0.030 |
Why?
| | Ambulatory Care | 1 | 2015 | 168 | 0.030 |
Why?
| | Neoplasm Staging | 2 | 2011 | 1858 | 0.030 |
Why?
| | Survivors | 1 | 2015 | 201 | 0.030 |
Why?
| | Survival Analysis | 2 | 2004 | 1519 | 0.030 |
Why?
| | Continuity of Patient Care | 1 | 2015 | 165 | 0.030 |
Why?
| | United States | 2 | 2004 | 6050 | 0.030 |
Why?
| | Disease-Free Survival | 2 | 2006 | 1175 | 0.030 |
Why?
| | Risk Factors | 2 | 2015 | 5099 | 0.030 |
Why?
| | Cyclophosphamide | 1 | 1992 | 280 | 0.030 |
Why?
| | Prospective Studies | 1 | 2020 | 3870 | 0.030 |
Why?
| | Doxorubicin | 1 | 1992 | 277 | 0.030 |
Why?
| | Androstadienes | 1 | 2012 | 72 | 0.030 |
Why?
| | Outpatients | 1 | 2012 | 81 | 0.030 |
Why?
| | Nitriles | 1 | 2012 | 140 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2020 | 2254 | 0.030 |
Why?
| | Triazoles | 1 | 2012 | 95 | 0.030 |
Why?
| | Fluorouracil | 1 | 1992 | 537 | 0.030 |
Why?
| | Male | 3 | 2015 | 39419 | 0.030 |
Why?
| | History, 20th Century | 1 | 1992 | 303 | 0.030 |
Why?
| | Oncogenes | 1 | 1989 | 87 | 0.020 |
Why?
| | Axilla | 1 | 1989 | 92 | 0.020 |
Why?
| | Receptors, Estrogen | 1 | 1990 | 375 | 0.020 |
Why?
| | Retrospective Studies | 2 | 2012 | 7386 | 0.020 |
Why?
| | Receptors, Cell Surface | 1 | 1989 | 286 | 0.020 |
Why?
| | Cell Division | 1 | 1989 | 703 | 0.020 |
Why?
| | Medical Oncology | 1 | 2011 | 323 | 0.020 |
Why?
| | Incidence | 1 | 2012 | 1528 | 0.020 |
Why?
| | Treatment Outcome | 2 | 2011 | 7469 | 0.020 |
Why?
| | Carcinoma, Lobular | 1 | 2006 | 78 | 0.020 |
Why?
| | Lymph Nodes | 1 | 1989 | 507 | 0.020 |
Why?
| | Body Weight | 1 | 2006 | 457 | 0.020 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2006 | 151 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2006 | 823 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2006 | 845 | 0.020 |
Why?
| | Taxoids | 1 | 2004 | 127 | 0.020 |
Why?
| | Young Adult | 1 | 2015 | 5701 | 0.020 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2004 | 349 | 0.020 |
Why?
| | Cell Differentiation | 1 | 1989 | 1417 | 0.020 |
Why?
| | Up-Regulation | 1 | 2004 | 688 | 0.010 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2004 | 1163 | 0.010 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2004 | 898 | 0.010 |
Why?
|
|
Merkel's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|